Inventor · disambiguated record
Klaus Charisse
Also filed as: CHARISSE KLAUS
42 granted patents·33 pending applications·448 citations·filing 2010–2025
98Inventor score
Files withALNYLAM PHARMACEUTICALS INC66GENZYME CORP3BETTENCOURT BRIAN2ALNYLAM PHAMACEUTICALS INC1ALNYLAM PHARMACEUTICALS1
Top patents by PatentIndex Score
75 records- 0199US9796974B2Modified RNAi agentsALNYLAM PHARMACEUTICALS INC·Filed 2012·Granted Oct 24, 2017·119 cites·30 claims
- 0298US11406716B2Modified RNAi agentsALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Aug 9, 2022·8 cites·21 claims
- 0398US10668170B2Modified RNAi agentsALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Jun 2, 2020·22 cites·22 claims
- 0498US9399775B2RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseasesALNYLAM PHARMACEUTICALS INC·Filed 2012·Granted Jul 26, 2016·51 cites·36 claims
- 0598US9249415B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Feb 2, 2016·24 cites·30 claims
- 0696US11873491B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Jan 16, 2024·2 cites·32 claims
- 0796US11504391B1Modified RNA agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Nov 22, 2022·18 cites·42 claims
- 0896US10988768B2TMPRSS6 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Apr 27, 2021·3 cites·21 claims
- 0996US9850488B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Dec 26, 2017·11 cites·62 claims
- 1096US9701963B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted Jul 11, 2017·9 cites·32 claims
- 1196US9127274B2Serpinc1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS·Filed 2013·Granted Sep 8, 2015·51 cites·62 claims
- 1295US9783806B2TMPRSS6 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Oct 10, 2017·16 cites·30 claims
- 1394US11419942B2Angiotensinogen (AGT) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Aug 23, 2022·2 cites·55 claims
- 1494US10995336B2Serpina1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted May 4, 2021·8 cites·41 claims
- 1594US10913950B2TMPRSS6 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Feb 9, 2021·5 cites·20 claims
- 1694US10570391B2RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseasesALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted Feb 25, 2020·12 cites·45 claims
- 1794US10238749B2Angiotensinogen (AGT) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Mar 26, 2019·12 cites·44 claims
- 1893US9574192B2Serapina1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2014·Granted Feb 21, 2017·14 cites·36 claims
- 1992US10814007B2Angiotensinogen (AGT) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Oct 27, 2020·3 cites·15 claims
- 2091US9376680B2Serpinc1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Jun 28, 2016·7 cites·55 claims
- 2191US9228188B2Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expressionBETTENCOURT BRIAN·Filed 2012·Granted Jan 5, 2016·8 cites·22 claims
- 2290US11162098B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Nov 2, 2021·2 cites·19 claims
- 2390US10030244B2Serpina1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Jul 24, 2018·6 cites·28 claims
- 2490US9725718B2Compositions and methods for inhibition of expression of protein C (PROC) genesALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Aug 8, 2017·3 cites·33 claims
- 2589US2025064943A1ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2688US11725207B2Serpina1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Aug 15, 2023·1 cites·123 claims
- 2788US2024279652A1RNAi AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASESALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2888US2024309387A1TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2987US10125369B2PCSK9 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2013·Granted Nov 13, 2018·9 cites·85 claims
- 3087US9970006B2Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genesALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted May 15, 2018·4 cites·15 claims
- 3187US9187746B2Dual targeting siRNA agentsFITZGERALD KEVIN·Filed 2010·Granted Nov 17, 2015·3 cites·20 claims
- 3286US2024110180A1Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genesALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3385US11597932B2Chirally-enriched double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Mar 7, 2023·3 cites·24 claims
- 3485US10683504B2Serpina1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Jun 16, 2020·2 cites·19 claims
- 3585US9068184B2Compositions and methods for inhibition of expression of protein C (PROC) genesTOUDJARSKA IVANKA·Filed 2012·Granted Jun 30, 2015·5 cites·24 claims
- 3685US2023365965A1SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOFGENZYME CORP·Filed 2023·Application pending·0 cites
- 3785US2025207131A1Modified rna agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3884US12290573B2Modified RNAi agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted May 6, 2025·0 cites·20 claims
- 3984US10920223B2Serpina1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Feb 16, 2021·2 cites·45 claims
- 4083US12005074B2Extrahepatic deliveryALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted Jun 11, 2024·0 cites·28 claims
- 4183US2025043279A1SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 4283US2024358738A1Extrahepatic deliveryALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 4382US2025213720A1MODIFIED RNAi AGENTSALNYLAM PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 4481US2023123192A1ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4580US9315813B2Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genesBETTENCOURT BRIAN·Filed 2012·Granted Apr 19, 2016·3 cites·17 claims
- 4679US12275938B2Modified RNA agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Apr 15, 2025·0 cites·38 claims
- 4778US11118181B2Compositions and methods for inhibition of expression of protein C (PROC) genesALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Sep 14, 2021·0 cites·20 claims
- 4878US2021388360A1Compositions and methods for inhibition of expression of protein c (proc) genesALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4977US12071619B2SERPINA1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Aug 27, 2024·0 cites·18 claims
- 5077US2023010288A1Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseasesALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 75 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Klaus Charisse files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →